You just read:

Blueprint Medicines Publication in Cancer Discovery Highlights Preclinical and Clinical Proof-of-Concept Data for Highly Selective RET Inhibitor BLU-667

News provided by

Blueprint Medicines

Apr 15, 2018, 09:35 ET